Search

Displaying all 5 results
DrugBest match

Deucravacitinib

go.drugbank.com/drugs/DB16650
ApprovedInvestigational

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target. This selec...

  1. Pathway

    Deucravacitinib Drug Metabolism

    smpdb.ca/view/SMP0130659
    Metabolic

    Deucravacitinib passes through the liver and is then excreted from the body mainly through the kidney. … Deucravacitinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis.

    Drugs: Deucravacitinib
  2. Indication

    Moderate Plaque psoriasis

    go.drugbank.com/conditions/DBCOND0020390
    Drugs: Bimekizumab · Brodalumab · Clobetasol propionate · Deucravacitinib · Etanercept · Guselkumab +3 more
  3. Indication

    Severe Plaque psoriasis

    go.drugbank.com/conditions/DBCOND0025583
    Drugs: Bimekizumab · Brodalumab · Clobetasol propionate · Deucravacitinib · Etanercept · Guselkumab +3 more
  4. Indication

    Active Psoriatic arthritis

    go.drugbank.com/conditions/DBCOND0020384
    Drugs: Apremilast · Bimekizumab · Certolizumab pegol · Deucravacitinib · Golimumab · Guselkumab +5 more